Filtreler
Comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury: an experimental study

Araz, Omer | Demirci, Elif | Ucar, Elif Yilmazel | Calik, Muhammet | Pulur, Didem | Karaman, Adem | Yayla, Muhammed

Article | 2013 | MULTIDISCIPLINARY RESPIRATORY MEDICINE8

Background: Different medical therapies are employed in acute lung injury (ALI) but there is still a debate about the efficacy of these drugs. Among these therapies steroids are clinically applied and bosentan is experimentally studied. The aim of this study was to evaluate the efficacy of these two drugs to treat inflammation in ALI by histopathological comparison. Methods: The five experimental groups (n = 5 per group) were: saline control (Group I); lipopolysaccharide (LPS) + saline (Group II); LPS + dexamethasone (Group III); LPS + 50 mg/kg bosentan (Group IV); and LPS + 100 mg/kg bosentan (Group V). Bosentan was administered or . . .ally one hour before and 12 hours after LPS treatment. Dexamethasone was administered intraperitoneally in three doses of 1 mg/kg; one dose was co-administered with LPS and the other two doses were given respectively 30 minutes before and after LPS treatment. Vasodilation-congestion, hemorrhage, polymorphonuclear leukocyte (PMN) infiltration, mononuclear leukocyte (MNL) infiltration, alveolar wall thickening, alveolar destruction/emphysematous appearance, and focal organization were the parameters used as criteria for evaluating inflammation and efficacy of treatment. Results: Compared to the LPS-only group (Group II), dexamethasone treatment (Group III) resulted in significant improvements in vasodilation-congestion, hemorrhage, PMN and MNL infiltration, alveolar wall thickening and emphysematous areas. Treatment with 50 mg/kg dose of bosentan (Group IV) also resulted in significant improvements in hemorrhage, PMN and MNL infiltration, alveolar wall thickening and alveolar destruction. Reducing lung injury and reparative effects of 100 mg/kg bosentan were significant in all parameters. Conclusions: Bosentan is as effective as dexamethasone for treating lung injury in ALI. Bosentan at 100 mg/kg can be recommended as a first treatment choice based on its significant reducing lung injury and reparative effects Daha fazlası Daha az

Role of angiotensin and endothelin in testicular ischemia reperfusion injury

Türkili, Burak | Kurçer, Zehra | Dengiz-Özbakış, Günnur | Kandemir-Onak, Nilüfer | Mungan, Görkem | Özaçmak, Veysel Haktan | Banoğlu, Zekeriya Nur

Article | 2012 | International Journal of Urology19 ( 3 ) , pp.257 - 263

Objectives: To determine whether angiotensin and endothelin have any role in testicular ischemia reperfusion injury by investigating the effects of the angiotensin converting enzyme inhibitor enalapril, selective non-peptide angiotensin-II type I blocker losartan and dual endothelin receptor blocker bosentan. Methods: Rats were anesthetized with thiopental sodium (50mg/kg i.p.) before the operation. The left testicular artery and vein of rats were occluded for 1h; before the bilateral orchiectomy, the organ was allowed to reperfuse for 3h or 24h. Enalapril (20mg/kg i.p.), losartan (30mg/kg i.p.), bosentan (10mg/kg i.p.) or vehicle ( . . .saline) were given 30min before reperfusion. Malondialdehyde level was measured in testicular tissue after 3h of reperfusion. Histological examination was carried out after 24h of reperfusion. Results: Ischemia reperfusion caused a significant increase in malondialdehyde level of ipsilateral testis, and histopathological injury in both ipsilateral and contralateral testes. Enalapril, losartan and bosentan treatments prevented the ischemia reperfusion-induced augmentation in malondialdehyde levels. Only bosentan treatment ameloriated ischemia reperfusion-induced histopathological alterations. Conclusions: Endothelin might play a more important role in pathogenesis of testicular ischemia reperfusion injury when compared with angiotensin. © 2011 The Japanese Urological Association Daha fazlası Daha az

6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms